UCB Pharma’s Celltech Antibody Research Centre of Excellence and Millennium Pharmaceuticals entered into an agreement for the research, development and commercialization of treatments for inflammation. The collaboration will focus on developing antibody therapeutics generated from two validated Millennium targets.